Form 4 Filing for Davidson Matt - Officer/Director Change

This filing details transactions made by Davidson Matt, Chief Development Officer and Director of ADIAL PHARMACEUTICALS, INC. On June 11, 2026, Matt Davidson acquired 61,647 shares of Common Stock and 1,822.13 shares of Series A Preferred Stock directly. Additionally, the Matt and Alli Davidson Trust acquired 3,427 shares of Common Stock and 101.298 shares of Series A Preferred Stock. On June 12, 2026, Davidson acquired 232,417 shares of Common Stock and a stock option to purchase 232,417 shares of Common Stock. These transactions were part of a merger involving Azora Therapeutics, Inc. and the issuance of restricted stock units vesting over 36 months. The Series A Preferred Stock is convertible into common stock.